A Study to Evaluate Efficacy and Safety of HGP2304 in Essential Hypertension Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 356 participants.
Also called NCT06174766
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 356 participants
- Registry
-
NCT06174766
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT06174766. Randomized; double masking; primary purpose treatment. Start 2024-05-10 (actual); primary completion 2026-01-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Efficacy and Safety of HGP2304 in Essential Hypertension Patients
- Condition
- Hypertension
- Intervention (Drug)
- HGP2304-1
- Intervention (Drug)
- HGP2304-2
- Intervention (Drug)
- RLD2209-1
- Intervention (Drug)
- RLD2209-2
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct06174766- Content hash
72ee63760b129f234fd02430abfa64d45b7b635ff57ad53e561dbfbc9b6e4bf1